Pfizer Inc. is reviewing strategic alternatives for its Consumer Healthcare business. All options are on the table including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business.
“Pfizer Consumer Healthcare is a leading player in the largest OTC categories, with iconic brands, robust retail partnerships, global reach and strong fundamentals,” said Ian Read, Pfizer Chairman and Chief Executive Officer. “Although there is a strong connection between Consumer Healthcare and elements of our core biopharmaceutical businesses, it is also distinct enough from our core business that there is potential for its value to be more fully realized outside the company. By exploring strategic options, we can evaluate how best to fuel the future success and expansion of Consumer Healthcare while simultaneously unlocking potential value for our shareholders.”
Pfizer Consumer Healthcare develops, manufactures and markets leading non-prescription medicines, vitamins, and personal care products.
Major categories and product lines include:
• Dietary Supplements: Centrum, Caltrate, and Emergen-C
• Pain Management: Advil and Thermacare
• Gastrointestinal: Nexium 24 Hour and Preparation H
• Respiratory: Robitussin and Advil Cold and Sinus
• Personal Care: ChapStick and Anbesol